Por favor, use este identificador para citar o enlazar este ítem:
10.1111/jvp.12442
Twittear
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Escudero, Ana I. | - |
dc.contributor.author | Marín, Pedro | - |
dc.contributor.author | Cárceles Rodríguez, Carlos | - |
dc.contributor.author | Escudero, Elisa | - |
dc.contributor.other | Facultades, Departamentos, Servicios y Escuelas::Departamentos de la UMU::Farmacología | es |
dc.date.accessioned | 2021-03-24T16:20:53Z | - |
dc.date.available | 2021-03-24T16:20:53Z | - |
dc.date.issued | 2018-02 | - |
dc.identifier.uri | http://hdl.handle.net/10201/105601 | - |
dc.description.abstract | The pharmacokinetic of deflazacort after intravenous and oral administration and the effect of erythromycin on the disposition of deflazacort in rabbits were investigated. A parallel study was carried out in twelve rabbits. The plasma concentration-time profiles of deflazacort were determined after intravenous and oral administration of single dosages of 5 mg/kg in the presence and absence (baseline) of multiple dose erythromycin regimens. Plasma levels of 21-desacetyldeflazacort were determined by HPLC. Plasma concentration-time curves were analysed by compartmental pharmacokinetic and non-compartmental methods. The t½z values following intravenous and oral administration were 3.67 and 4.96 h, respectively. The apparent volume of distribution at steady state (Vss) was 4.08 ± 0.31 L/kg, this value indicates that deflazacort is widely distributed into the extravascular tissues. Moreover, bioavailability after oral administration of deflazacort (F = 87.48 %) was high. Pharmacokinetic analysis after both routes of administration revealed a significant reduction in total body clearance, a significant increase in mean residence time, half-life and plasma concentrations of the steroid in the presence of multiple dose erythromycin. The results indicated the influence of the erythromycin on deflazacort disposition, which is consistent with a pharmacokinetic-type interaction in the elimination of the drug from the body. Moreover this interaction should be considered to avoid adverse effects when using both drugs concomitantly. | es |
dc.format | application/pdf | es |
dc.format.extent | 18 | es |
dc.language | eng | es |
dc.relation | Sin financiación externa a la Universidad | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Deflazacort; erythromycin; interaction; pharmacokinetics; rabbits. | es |
dc.title | PHARMACOKINETICS OF DEFLAZACORT IN RABBITS AFTER INTRAVENOUS AND ORAL ADMINISTRATION AND ITS INTERACTION WITH ERYTHROMYCIN | es |
dc.title.alternative | ERYTHROMYCIN EFFECT ON DEFLAZACORT DISPOSITION | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.doi | 10.1111/jvp.12442 | - |
Aparece en las colecciones: | Artículos: Farmacología |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Deflazacort.pdf | Deflazacort erythromycin interaction | 233,85 kB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons